Ali Behbahani
Director; Director, 10% Owner · 15 filings · Latest: Sep 18, 2026
Arcellx, Inc.
Black Diamond Therapeutics, Inc.
CRISPR Therapeutics AG
Korro Bio, Inc.
Monte Rosa Therapeutics, Inc.
Nkarta, Inc.
SpyGlass Pharma, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
CRSP | Ali Behbahani | Director | Sep 17, 2026 | Sale | $57.09 | 13,679 | $780.9K | 16,637 | |
CRSP | Ali Behbahani | Director | Sep 17, 2026 | Option Exercise | $14.00 | 30,000 | $420.0K | 30,316 | |
CRSP | ALI BEHBAHANI | — | Sep 17, 2026 | Proposed Sale | $57.09 | 13,679 | $780.9K | — | |
SGP | Ali Behbahani | Director, 10% Owner | Feb 9, 2026 | Purchase | $16.00 | 937,500 | $15.0M | 6,035,038 | |
CVRX | Behbahani Ali | — | Nov 29, 2024 | Proposed Sale | $15.30 | 21,837 | $334.1K | — | |
CVRX | Behbahani Ali | — | Nov 18, 2024 | Proposed Sale | $14.07 | 9 | $127 | — |